An HIV vaccine - Challenges and prospects

New England Journal of Medicine

Volumn 359, Issue 9, 2008, Pages 888-890

  Johnston, Margaret I ^a   Fauci, Anthony S ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NIAID ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; T CELL VACCINE; UNCLASSIFIED DRUG;

CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; GENE MUTATION; GENETIC VARIABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; PRIORITY JOURNAL; SHORT SURVEY; VIRUS REPLICATION;

EID: 50449090525     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp0806162     Document Type: Article

References (5)

1. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A 1998;95:8869-73.
2. Burton DR, Desrosiers RC, Doms RW, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004;5:233-6.
3. Johnston MI, Fauci AS. An HIV vaccine - evolving concepts. N Engl J Med 2007;356:2073-81.
4. Goulder PJR, Watkins DI. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nat Rev Immunol 2008;8:619-30.
5. Fauci AS, Johnston MI, Dieffenbach CW, et al. HIV vaccine research: the way forward. Science 2008;321:530-2.